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Summanr The clinical importance of microvessel quantitation as a prognostic indicator in invasive breast
cancer was examined. This study included 155 patients with invasive breast cancer. with a median follow-up of
82 months. Microvessels were identified by immunohistochemical staining for factor VIII-related antigen in
formalin-fixed. paraffin-embedded primary tumours. For each tumour. microvessels were counted within a
200 x magnification field in the area of highest microvessel density. Microvessel counts (MVCs) had no
correlation with tumour size, lymph node status or histological grade. When patients were classified by MVC,
higher counts were associated with shorter disease-free survival and overall survival (P<0.025 and P<0.01
respectively). Multivariate analysis showed that MCV is an independent prognostic factor. Microvessel
quantitation may be a useful predictor for identifying breast cancer patients at high risk for relapse and
death.
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Axillary lymph node status has been considered the most
important prognostic factor in breast cancer, although it does
not fully account for the varied prognosis associated with
this disease. Approximately 20-30% of lymph node-negative
breast cancer patients will develop recurrent disease with
consequent risk of death within 10 years of the initial local
therapy (McGuire, 1989; Singurdsson et al., 1990; Osborne,
1992). Thus, new, reliable prognostic indicators that could
identify patients at high nrsk for recurrence and death could
prove useful in guiding treatment and decreasing mortality.
Growth and metastasis of cancer cells require several pro-
cesses, with angiogenesis playing a key role (Blood and
Zetter, 1990; Bicknell and Harris, 1991; Hart and Saini,
1992). The intensity of neovasculan'sation reflects tumour cell
angiogenic activity (Blood and Zetter, 1990; Folkman, 1990).
Microvessel density has been shown to be a prognostic pre-
dictor in patients with lung cancer (Macchiarini et al., 1992),
prostatic cancer (Weidner et al., 1993) and malignant mela-
noma (Srivasta et al., 1988). With regard to breast cancer,
Weidner et al. (1991) found a significant correlation between
microvessel density and the presence of metastatic disease.
They also reported a relationship between microvessel count
(MVC) and prognosis (Weidner et al.. 1992). Since mortality
in breast cancer is related to the occurrence of distant metas-
tasis, the histological quantitation of intra-tumour micro-
vessels may predict prognosis in some subsets of breast
cancer patients and provide useful information for deciding
therapeutic strategies.
The purpose of this study was to examine the correlation
between tumour (MVCs) and clinicopathological factors, and
to determine whether microvessel quantitation could identify
breast cancer patients at high risk for recurrence and death.
using immunohistochemical staining of formalin-fixed,
paraffin-embedded sections for factor VIII-related antigen.
Materials and metbods
Patients
The study population was composed of 155 women with
invasive breast cancer surgically treated at the First Depart-
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ment of Surgery, Osaka City University Hospital. between
1979 and 1985. The patients had primary, unilateral breast
cancer and no other primary cancer. Table I shows the
distribution of patient characteristics. All patients underwent
extensive, standard or modified radical mastectomy. Adju-
Table I Distribution of clinicopathological factors
MVC
High Low
Total (> 52.8} (<52.8}
Case number 155 70 85
Menopausal status
Premenopausal 73 36 37
Post-menopausal 82 34 48
Tumour size (cm)
<2 65 30 35
>2. < 5 74 32 42
>5 16 8 8
Number of lymph node metastases
0 91 40 51
1-3 26 9 17
>4 38 21 17
Clinical stage
I 49 22 27
II 64 26 38
III 42 22 20
Histological grade
1 80 35 45
11 52 22 30
111 23 13 10
Operation
Modified 32 17 15
Standard 71 32 39
Extended 52 21 31
Adjuvant therapy
None 27 12 15
Tamoxifen + Tegaful 36 13 23
Tegaful 70 31 39
Irradiation 6 4 2
CAF + irradiation 16 10 6
MVC, microvessels count; CAF, combination chemotherapy with
cyclophosphamide, doxorubicin and 5-fluorouracil. There was no
significant difference in the distribution of any factors by chi-square
test.r_ Y poa etaw
vant therapy was administered as shown in Table I. Tamox-
ifen (20mgday-') and Tegaful (600 mgday-') were admini-
stred for 2 years. Combination chemotherapy with CAF
(cyclophosphamide 100 mgday-' from day 1 to 14, doxo-
rubicin 30 mgm-2 and 5-fluorouracil 500mgm-2, i.v., on
day 1 and day 8) was given every 28 days for two or three
cycles. Lineac irradiation was given to the supraclavian and
parasternal regions to a total of 45-50Gy. All patients had
post-operative follow-up examinations monthly for the first
year and then every 6 months thereafter. Relapse-free sur-
vival and overall survival were calulated as the period from
surgery until the date of first recurrence or death.
Clinical outcome
Fifty patients relapsed: 15 with bone metastasis, 14 with lung
or pleural metastasis, five with liver meastasis and three with
brain metastasis. Thirteen patients relapsed loally. Forty
patients died from breast cancer and five died of other causes
during the follow-up period. The median follow-up was 82
months (range 4-174 months). The median length oftime to
relapse was 42 months (range 4-130 months).
Immunohistochemistry
Sections 4 zm thick were cut from resected primary tumours
which were formalin fixed and praffin embedded. We used
full cross-sections of each tumour for evaluation. These sec-
tions were stained for factor VII-related antigen using the
avidin-biotin-peroxidaw complex (ABC)-immunoperoxid-
ase method. Endothehal cells of tumour vessels were high-
lighted by this method. We used monoclonal antibody
against factor VIII-related anfigen (DAKO-vWF, F8/86,
Dakopatts, Denmark) and an ABC kit (Maxitags Lipshow,
Immunon, Pittsburgh PA, USA). After deparaffinisation in
xylene and washing in ethanoL sections were incubated for
30min in 0.3% hydrogen peroxide in methanol for blocking
of endogeneous peroxidase. After repeated washings in
phosphate-buffered saline (PBS), sections were predigest
with 0.1% trypsin (Difco, Detroit, MI, USA) at 37C for
30min to unmask hidden epitopes. Tlhreafter, the slides
were processed according to the standard method with the
Maxitags ABC kit. The monoclonal antibody F8/86 was
diluted 1:200 and rected with tis specmens at 3TC for
2 h. Diaminobenzidine was used as chromogen, followed by
haematoxylin countestaining. Normal mouse IgG was sub-
stituted for primary antibody as a negative control.
Microvessel quantitation
Microvessel quantitation was performed by light microscopy
by observers without knowledge of patients data. First, the
area of highest microvascular density of the tumour was
found by scanning at 40 x magnification, and then the single
field with the highest number of microvessels at 200 x
magnification (0.785 mm2 per field) was identified. Any
brown-stained endothelial cell that had clearly separated
from adjacent microvessels, tumour cells and other connec-
tive tissue elements was considered to be a single countable
microvessel. Undefined endothelial cells which appeared to be
fragments were not counted as microvessels. The presence of
a vessel lumen was not required to classify a structure as a
vessel. For each tumour, the MVC was asd indepen-
dently by three investigators. The average of these three
counts was taken as the MVC of the tumour. Figure 1 shows
a representative field from an invasive carcinoma stained for
factor VIII-related antigen.
Clinicopathological analysis
Tumour size and nodal status were determined from the
initial surgical pathology reports. Staging analysis was done
according to the International Union Against Cancer
tumour-nodes-metastasis classification established in 1987
(American Joint Committee on Cancer, 1988). Tumours were
graded histopathologically according to the Scarff-Bloom-
Richardson histologcal grading system (Bloom and Richard-
son. 1957; Scarff and Torloni, 1968). Tumour oestrogen
receptor (ER) status was determined in 53 cases by an
enzyme-labelled immunoassay method; any tumour with
more than 5 fmol ERmg-' protein was considered to be ER
positive.
Survival analysis
The mean MVC of all patients was used to classify patients
into high- and low-MVC groups. Relapse-free survival and
overall survival rate were compared between the two groups.
Statisticalanalysis
We used the Mann-Whitney test and the chi-square test to
evaluate clinicopathological factors. The relationship between
MVC and survival was examined by constructing Kaplan-
Meier survival curves and analysing differences by the log-
rank test. For multivariate analysis, stepwise logistic regres-
sion analysis was used. Two-tailed P-values less than 0.05
were considered to be significant.
Redts
MVC andclinicopathologicalfactors
Associations between MVC and cinicopathological factors
are shown in Table H. No significant difference in MVC was
seen in terms ofmenopausal status, tumour size, lymph node
status vessel invasion and histological grade. The MVC of
tumours with lymphatic invasion was significntly higher
than that of tumours without lymphatic invasion (P<0.05).
For the 53 cases in which ER status was determined, the
MVC of ER-negative tumours was significantly higher than
that of ER-positive tumours (P<0.01).
MVC anddisease relapse
The MVC of patients in whom relapsed disease presented as
distant metasasis within 10 years after surgery was
significantly higher than in patients not showing relapse after
a 10-year interval (P<0.001). On the other hand, no
signifiant difference in MVC was found between local
relaps patients and disease-free patients in a 10-year period
(Table H). Stratification by stage showed signiiant
differences in MVC between relapsing with distant metastasis
and disease-free patients for each stage group in a 10-year
period (Figure 2).
MVC andsurvival
The mean MVC ofall 155 patients, which was 52.8, was used
as-a cut-offpoint between high- and low-MVC groups. There
was no significant difference in the distribution of clinico-
pathological factors between the two groups (Table I).
The prognosis of high-MVC patients was significantly
poorer than that of low-MVC cases. Figure 3a shows a
difference in relape-free survival rate between the high-MVC
and low-MVC groups (P<0.025). Figure 3b shows a differ-
ence in overall survival rate between the two groups (P<
0.01). Stratification by nodal status showed that MVC was
related to the relapse-free survival rate in lymph node-
negative patients (P<0.01), but not in lymph node-positive
patients (Figure 4). In addition, MVC was related to the
overall survival rate both in lymph node-negative and lymph
node-positive patients (P<0.01 and P<0.025 respectively)
(Figure 5).
Multivariate analysis
MVC and other clinicopathological factors were analysed by
stepwise logistic regression analysis. As shown in Table HI,Micn-esel tareiimi in breastcanme
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FigteI Microvessel staining for factor VIII-related antigen by
the immunoperoxidase technique (200 x).
Fuge 2 Relationship between microvessel counts and relapses
presenting as distant metastasis for different clinical stages in a
10-year period. Microvessel count: stage I. disease free 45.0 ±
17.1, relapse 67.7 ± 25.2; stage II, disease free 49.8 ± 12.8. relapse
59.9 ± 15.8; stage III, disease free 41.3 ± 14.3, relapse 69.9 ± 13.3.
n = number of cases. *P<0.025. **P<0.025 and ***P<0.025
by Mann-Whitney test.
Table H Relationship of microvessel counts to clinicopathological
factors and disease relapse
Case nnber Mean MVC ± s.d.
Total 155 52.8± 18.8
Menopausal status
Premenopausal 73 54.5 16.6
Post-menopausal 82 51.3 ± 20.4
Tumour size (cm)
_<_2 65 53.6 20.8
>2, <5 74 51.3 16.6
>5 16 56.1 ± 18.8
Number of lymph node metastases
0 91 51.5±20.3
1-3 26 51.4± 16.6
)4 38 56.8±15.6
Lymphatic invasion
+ 10 65.9 18.3*
145 51.4 18.2*
Vessel invasion
+ 2 60.5±5.5
153 52.2 18.6
Histological grade
I 80 52.3 20.9
II 52 50.4 15.0
III 23 56.7 15.8
Oestrogen receptor
+ 28 45.5 16.6**
25 58.9 17.5**
Disease relapse in 10 year period
None 37 45.1 ± 15.2***
Local 12 44.3 13.4t
Distant 36 65.1 17.5*** t
*PP<0.05, **P<0.01, ***P<0.001 and tP<0.005 by
Mann-Whitney test.
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Fugue 3 (a) Relapse-free survival rate of patients with high and
low microvessel counts; P<0.025, log-rank test. (b) Overall sur-
vival rate of patients with high and low microvessel counts;
P<0.01, log-rank test.
MVC was an independent prognostic indicator. However, the
presence of lymph node metastasis had a greater predictive
value for disease recurrence than did MVC. In contrast,
MVC was a stronger predictor of death than lymph node
metastasis for death.
There is considerable expenrmental evidence that metastasis is
dependent on angiogenesis. Metastasis is a multistep process;
for a cancer cell to metastasise, it must breach a series of
barriers to gain access to the vasculature of the primary
tumour, survive in the circulation, lodge in the mincrovas-
culature of the target organ, exit from this vasculature and
proliferate in the target organ (Blood and Zetter, 1990; Bick-
nell and Harris, 1991; Hart and Saini, 1992). Without the
ability to recruit new vessels, most tumours would remain
localised to their primary site (Liotta et al., 1974). Thus,
angiogenesis is a necessary step for the beginning of the
metastatic cascade, but its basic underlying mechanisms are
largely unknown. Angiogenesis may facilitate metastasis by
several routes. The leaky nature of newly formed blood
vessels, compared with mature pre-existent vessels, may pro-
mote the entry of cancer cells into the bloodstream. In
addition, a greater number of tumour vessels increases the
probability that tumour cells will enter the circulation.
Degradative enzymes secreted from endothelial cells at the
tips of growing capillaries may allow the escape of cancer
cells into the neovasculature (Moscatelli et al., 1981; Blood
and Zetter, 1990).inawuud -~~~n lilil
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Fige 4 Stratification of relapse-free survival by nodal status
and MVC. The microvessel count predicted miapse-free survival
in node-negtive patients (P<0.01, log rant test), but not in
node-positive patients (P=0.087, log-rank test).
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Fge 5 Stratification of overall survival by nodal status and
MVC. The mirovessel count predict ovrall sunrival both in
node-neptive and node-positive patients (P<0.01 and P<0.025,
respeciively, log-rank test).
Table M Multivariate analysis of prognostic factors
Coefficient s.e. estimate t-statistic P-value
Disease recurrence
Constant -0.1085 0.1265 -0.8578 0.392
Menopausal status 0.1041 0.0670 1.5532 0.122
Tumour size 0.1255 0.0633 1.9829 0.049
Lymph node status 0.2599 0.0697 3.7268 0.001
Cinical stage -0.1229 0.1001 -1.2272 0.222
Lymphatic invasion -0.1197 0.1463 -0.8187 0.414
Vessel invasion -0.0834 0.3055 -0.2731 0.785
Histological grade 0.0895 0.0489 1.8308 0.069
Microvessel count 0.21% 0.0690 3.1822 0.002
Death
Constant -0.1402 0.1185 -1.1830 0.239
Menopausal status 0.0640 0.0628 1.0188 0.310
Tumour size 0.0513 0.0593 0.8654 0.388
Lymph node status 0.1740 0.0654 2.6919 0.008
Clnical stage -0.0418 0.0938 -0.4455 0.657
Lymphatic invasion 0.0051 0.1371 0.0375 0.970
Vesse invasion 0.0028 0.2864 0.0099 0.992
Histological grade 0.0787 0.0458 1.7181 0.088
Microvessel count 0.2296 0.0622 3.6904 0.001
Tumour growth is also dependent on angiogenesis.
Tumours cannot expand beyond 1-2 mml without sufficient
neovascularisation but can expand rapidly to 1-2 cm3 after
vasculaisation (Folk-man et al., 1966; Sutherland et al.,
1971). Thus, in the absence of neovascularisation, only small
populations of tumour cells (about 10' cells) can survive.
There is accumulating evidence that tumour growth is angio-
genesis dependent, since growth factors released from endo-
thelial cells stimulate tumour cells (Blood and Zetter, 1990;
Foliman, 1994). Weidner et al. (1992) have reported a
significant correlation between vessel count and tumour size
in breast cancer patients. In our study, vessel counts did not
increase in proportion to tumour size. Bosari et al. (1992)
have reported findings consistent with our results. These data
may be explained as follows: tumours require neovascularisa-
tion to expand to sizes greater than a few cubic millire,
but may not require much new vessel formation in propor-
tion to tumour size after growth over a few cubic centi-
metres.
Several studies (Bosari et al., 1992; Horak et al., 1992;
Weidner et al., 1992; Toi et al., 1993) have revealed a
significant association of MVC with the lymph node status of
breast cancer patients, supporting a relationship between
angiogenesis and metastasis to the lymphatic system. On the
other hand, Visscher et al. (1993) showed no relation between
MVC and lymph node status. According to our results,
MVC is correlated with lymphatic invasion. However, MVC
showed no correlation with lymph node metastasis.
Fox et al. (1994) reported no relation between MVC and
ER status. However, the MVC of ER-negative tumours was
higher than that of ER-positive tumours in our study. ER-
negative tumours show more malignant behaviour than ER-
positive tumours, and it is therefore possible that the
biological behaviour of breast cancer associated with MVC
might be affected by ER status. Further studies are needed to
determine whether ER status is directly related to angio-
genesis.
The capacity of tumour cells to induce angiogenesis does
not always correlate with malignancy. For example, typical
pulmonary carcinoid tumours are highly vascular but rarely
metastasise (Gould et al., 1983). In our study, MVC was not
related to tumour histological grade. However, Jensen et al.
(1982) have shown that angiogenicity identifies cell popula-
tions at risk for neoplastic transformation and precedes
histological evidence of hyperplasia or neoplasia.
As a prognostic predictor in breast cancer, Hall et al.
(1992) have reported MVC cannot predict disease relapse.
Van Hoef et al. (1993) demonstrated that MVC does not
reflect prognosis in lymph node-negative patients. On the
other hand, several investigators (Bosari et al., 1992; Horak
et al., 1992; Weidner et al., 1992; Toi et al., 1993; Gasparini
et al., 1994) have reported the significance of MVC as a
prognostic predictor. Our results demonstrate a significant
difference in relapse-free survival and overall survival rates
between high- and low-MVC groups. Differences in both
relapse-free survival and overall survival were also seen in
lymph node-negative patients in different MVC groups, as
well as differences in overall survival in lymph node-positive
patients. Tumour metastasis occurs via both the blood cir-
culation and lymphatic system; however, mortality in breast
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cancer is due mainly to the former. The significance of MVC
as a prognostic indicator for death might best be demon-
strated by multivanrate analysis.
Microvessel quantitation may be used as an indicator of
the existence of occult systemic metastasis in breast cancer
patients with no clinical evidence of metastatic disease as well
as a predictor of death in breast cancer patients. Such in-
formation could prove useful for deciding on the need for
adjuvant therapy so as to reduce morbidity and motality
from breast cancer.
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